Evidence map›Paper›PMID 24757118›Full record

ReviewMovement disorders : official journal of the Movement Disorder Society2014

Cognition in movement disorders: where can we hope to be in ten years?

David Burn, Daniel Weintraub, Bernard Ravina, Irene Litvan

Open access · greenAbstract readReview
In one paragraph

Review in Movement disorders : official journal of the Movement Disorder Society, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed, 1 pooled it
1.7field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

17 citing papers in PubMed, 1 synthesis or guideline pooled it, 20 citations in OpenAlex.

  1. Pooled it
  2. A Metacognitive Strategy Intervention for People With Parkinson's Disease: Pilot and Feasibility Trial.The American journal of occupational therapy : official publication of the American Occupational Therapy Association · 2025
    Trial
  3. Trial
  4. Article
  5. Article
  6. Efficacy and Feasibility of the CO-OP Approach in Parkinson's Disease: RCT Study Protocol.Canadian journal of occupational therapy. Revue canadienne d'ergotherapie · 2023
    Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Review
  12. Article
  13. Article
  14. Parkinson's Disease: Cognitive Impairment.Focus (American Psychiatric Publishing) · 2017
    Review
  15. Overview of Neurocognitive Disorders.Focus (American Psychiatric Publishing) · 2017
    Review
  16. Review
  17. Introduction: the importance of cognition in movement disorders.Movement disorders : official journal of the Movement Disorder Society · 2014
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 4 institutions in 2 countries.

David BurnInstitute for Aging and Health, Newcastle University, Newcastle upon Tyne, UK.
Daniel Weintraub
Bernard Ravina
Irene Litvan
Biogen (United States) · USNewcastle University · GBUniversity of California, San Diego · USUniversity of Pennsylvania · US

Funding

Project IV: "Alpha-Synuclein Strains & Diverse Synucleinopathies"P50NS053488 · NINDS · UNIVERSITY OF PENNSYLVANIA · PI TROJANOWSKI, JOHN Q. · 2007 to 2017
$20.9M
Genetic and Environmental Risk Factors for PSPR01AG024040 · NIA · UNIVERSITY OF LOUISVILLE · PI LITVAN, IRENE · 2006 to 2010
$2.7M
NIA NIH HHS 5R01AG024040NIA NIH HHS R01 AG024040NINDS NIH HHS P50 NS053488
6 · The paper itself

Abstract

Cognitive impairment and dementia associated with movement disorders represent a major management challenge and area of unmet need. This article has focused upon Parkinson's disease as an exemplar condition, but many of the roadblocks and efforts to overcome these are applicable, in a general sense, to other disorders. Short of a "penicillin moment"-a chance discovery or piece of unintended good fortune-progress is likely to be incremental. Cognitive therapies may end up being multiple and possibly multimodal, parallel with the cancer therapy field. Ultimately, benefit for one condition may extend to others as commonality in protein aggregation, synergistic pathological effects between proteins, and pathological spread emerges. © 2014 International Parkinson and Movement Disorder Society.

Indexed as

AnimalsBiomarkersCognitionCognition DisordersDementiaHumansMovement DisordersBiomarkersbiomarkerscognitive testingdementiaParkinson's diseasetherapeutics

Identifiers

PMID24757118
PMCPMC4371593
OpenAlexW2156973490

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.